[Effects of butylphthalide on plasma nitric oxide and endothelin-1 in severe elderly OSAHS patients].

Objective:To investigate the effect of butylphthalide on plasma nitric oxide(NO) and endothelin-1(ET-1) in severe elderly OSAHS patients. Method:A total of 120 severe elderly OSAHS patients were chosen by PSG measurement. According to random number table method, OSAHS patients were randomly divided into non-invasive ventilation control group(n=40), butylphthalide treatment group(n=40) and butylphthalide combined with non-invasive ventilation group (n=40). Non-invasive ventilation control group was given double level airway positive pressure ventilation treatment for six months, butylphthalide treatment group accepted oral butylphthalide therapy for six months, butylphthalide combined with non-invasive ventilation group was given double level airway positive pressure ventilation treatment and accepted oral butylphthalide therapy for six months. The changes of plasma NO and ET-1 were detected by immunoenzyme adsorption before treatment and three and six months after treatment. Result:The difference of plasma NO and ET-1 before treatment in the three groups was not statistically significant (P>0.05). Compared with before treatment, the level of plasma NO decreased and the level of plasma ET-1 increased in the three groups after three and six months treatment (P<0.01). Compared with butylphthalide treatment group, the level of plasma NO increased and the level of plasma ET-1 decreased after 3 and 6 months of treatment in both non-invasive ventilation control group and butylphthalide combined with non-invasive ventilation group (P<0.05). Compared with non-invasive ventilation control group, the level of plasma NO increased and the level of plasma ET-1 decreased after 3 and 6 months of treatment in butylphthalide combined with non-invasive ventilation group (P<0.05). Conclusion:Butylphthalide may improve the vascular endothelial function of severe elderly OSAHS patients by increasing the level of NO and decreasing the level of ET-1 in plasma.目的：探讨丁苯酞对重度老年OSAHS患者血浆一氧化氮（NO）和内皮素-1（ET-1）的影响及临床意义。方法：将120例经PSG确诊的重度老年OSAHS患者随机分为无创呼吸机对照组、丁苯酞治疗组和丁苯酞联合无创呼吸机组，每组40例。无创呼吸机对照组患者行双水平气道正压通气治疗6个月，丁苯酞治疗组患者口服丁苯酞治疗6个月，丁苯酞联合无创呼吸机组患者在行双水平气道正压通气治疗的同时，口服丁苯酞治疗6个月，分别于治疗前及治疗3、6个月后采用免疫酶联吸附法检测血浆NO、ET-1水平的变化，并进行对比分析。结果：3组患者治疗前血浆NO和ET-1比较差异无统计学意义（P>0.05）；与治疗前比较，3组患者治疗3、6个月后血浆NO水平升高，ET-1水平下降（P<0.01）；与丁苯酞治疗组治疗后比较，无创呼吸机对照组及丁苯酞联合无创呼吸机组患者治疗3、6个月后血浆NO水平升高，ET-1水平下降，差异有统计学意义（P<0.05）；与无创呼吸机对照组比较，丁苯酞联合无创呼吸机组患者治疗3、6个月后血浆NO水平升高，ET-1水平下降，差异有统计学意义（P<0.05）。结论：丁苯酞可通过升高血浆NO、降低血浆ET-1的水平改善重度老年OSAHS患者的血管内皮功能。.